Literature DB >> 22056833

Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.

Deepak Kumar Bhateja1, Dinesh K Dhull, Aneet Gill, Akramdeep Sidhu, Saurabh Sharma, B V Krishna Reddy, Satyanarayana S V Padi.   

Abstract

Peroxisome proliferators activated receptor is regarded as potential therapeutic targets to control various neurodegenerative disorders. However, none of the study has elucidated its effect in the treatment of Huntington's disease. We explored whether peroxisome proliferators activated receptor-α agonist may attenuate various behavioral and biochemical alterations induced by systemic administration of 3-nitropropionic acid (3-NP), an accepted experimental animal model of Huntington's disease phenotype. Intraperitoneal administration of 3-NP (20mg/kg., i.p.) for 4days in rats produced hypolocomotion, muscle incoordination, and cognitive dysfunction. Daily treatment with fenofibrate (100 or 200mg/kg., p.o.), 30min prior to 3-NP administration for a total of 4days, significantly improved the 3-NP induced motor and cognitive impairment. Biochemical analysis revealed that systemic 3-NP administration significantly increased oxidative and nitrosative stress (increase lipid peroxidation, protein carbonyls and nitrite level), lactate dehydrogenase activity whereas, decreased the activities of catalase, superoxide dismutase, reduced glutathione, and succinate dehydrogenase. Fenofibrate treatment significantly attenuated oxidative damage, cytokines and improved mitochondrial complexes enzyme activity in brain. In the present study, MK886, a selective inhibitor of peroxisome proliferators activated receptor-α was employed to elucidate the beneficial effect through either receptor dependent or receptor independent neuroprotective mechanisms. Administration of MK886 (1mg/kg, i.p.) prior to fenofibrate (200mg/kg, p.o.) abolished the effect of fenofibrate. The results showed that receptor dependent neuroprotective effects of fenofibrate in 3-NP administered rats provide a new evidence for a role of PPAR-α activation in neuroprotection that is attributed by modulating oxidative stress and inflammation.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056833     DOI: 10.1016/j.ejphar.2011.10.029

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  The peroxisomal proliferator-activated receptor (PPAR) α agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment.

Authors:  Dana Greene-Schloesser; Valerie Payne; Ann M Peiffer; Fang-Chi Hsu; David R Riddle; Weiling Zhao; Michael D Chan; Linda Metheny-Barlow; Mike E Robbins
Journal:  Radiat Res       Date:  2014-01-07       Impact factor: 2.841

2.  Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia.

Authors:  Mariana I Holubiec; Juan I Romero; Juan Suárez; Manuel Portavella; Emilio Fernández-Espejo; Eduardo Blanco; Pablo Galeano; Fernando Rodríguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2018-07-29       Impact factor: 4.530

3.  Nicotinamide reverses behavioral impairments and provides neuroprotection in 3-nitropropionic acid induced animal model ofHuntington's disease: implication of oxidative stress- poly(ADP- ribose) polymerase pathway.

Authors:  Akram Sidhu; Vishal Diwan; Harsimran Kaur; Deepak Bhateja; Charan K Singh; Saurabh Sharma; Satyanarayana S V Padi
Journal:  Metab Brain Dis       Date:  2018-07-27       Impact factor: 3.584

4.  Lipid lowering agents, cognitive decline, and dementia: the three-city study.

Authors:  Marie-Laure Ancelin; Isabelle Carrière; Pascale Barberger-Gateau; Sophie Auriacombe; Olivier Rouaud; Spiros Fourlanos; Claudine Berr; Anne-Marie Dupuy; Karen Ritchie
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  PPARα/γ antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats.

Authors:  Xi Zhao; Feng Wang; Ruijun Zhou; Zengyan Zhu; Meilin Xie
Journal:  Inflammopharmacology       Date:  2017-02-25       Impact factor: 4.473

6.  Puerarin ameliorates 3-nitropropionic acid-induced neurotoxicity in rats: possible neuromodulation and antioxidant mechanisms.

Authors:  Heba M Mahdy; Mohamed R Mohamed; Manal A Emam; Amr M Karim; Ashraf B Abdel-Naim; Amani E Khalifa
Journal:  Neurochem Res       Date:  2013-12-18       Impact factor: 3.996

7.  Protective and antioxidant effects of PPARα in the ischemic retina.

Authors:  Elizabeth Moran; Lexi Ding; Zhongxiao Wang; Rui Cheng; Qian Chen; Robert Moore; Yusuke Takahashi; Jian-xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-13       Impact factor: 4.799

8.  Involvement of peroxisome proliferator-activated receptor β/δ (PPAR β/δ) in BDNF signaling during aging and in Alzheimer disease: possible role of 4-hydroxynonenal (4-HNE).

Authors:  Elisabetta Benedetti; Barbara D'Angelo; Loredana Cristiano; Erica Di Giacomo; Francesca Fanelli; Sandra Moreno; Francesco Cecconi; Alessia Fidoamore; Andrea Antonosante; Roberta Falcone; Rodolfo Ippoliti; Antonio Giordano; Annamaria Cimini
Journal:  Cell Cycle       Date:  2014-03-04       Impact factor: 4.534

Review 9.  Neuroprotection in diabetic retinopathy.

Authors:  Cristina Hernández; Rafael Simó
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

10.  Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats.

Authors:  Dirleise Colle; Danúbia Bonfanti Santos; Eduardo Luiz Gasnhar Moreira; Juliana Montagna Hartwig; Alessandra Antunes dos Santos; Luciana Teixeira Zimmermann; Mariana Appel Hort; Marcelo Farina
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.